| Literature DB >> 32599690 |
Marcela A S Pinhel1,2, Natália Y Noronha1, Carolina F Nicoletti1, Vanessa Ab Pereira1, Bruno Ap de Oliveira1, Cristiana Cortes-Oliveira1, Wilson Salgado1, Fernando Barbosa3, Júlio S Marchini1, Doroteia Rs Souza2, Carla B Nonino1.
Abstract
Weight regulation and the magnitude of weight loss after a Roux-en-Y gastric bypass (RYGB) can be genetically determined. DNA methylation patterns and the expression of some genes can be altered after weight loss interventions, including RYGB. The present study aimed to evaluate how the gene expression and DNA methylation of PIK3R1, an obesity and insulin-related gene, change after RYGB. Blood samples were obtained from 13 women (35.9 ± 9.2 years) with severe obesity before and six months after surgical procedure. Whole blood transcriptome and epigenomic patterns were assessed by microarray-based, genome-wide technologies. A total of 1966 differentially expressed genes were identified in the pre- and postoperative periods of RYGB. From these, we observed that genes involved in obesity and insulin pathways were upregulated after surgery. Then, the PIK3R1 gene was selected for further RT-qPCR analysis and cytosine-guanine nucleotide (CpG) sites methylation evaluation. We observed that the PI3KR1 gene was upregulated, and six DNA methylation CpG sites were differently methylated after bariatric surgery. In conclusion, we found that RYGB upregulates genes involved in obesity and insulin pathways.Entities:
Keywords: DNA methylation; bariatric surgery; gene expression; insulin; microarray; obesity; weight loss
Year: 2020 PMID: 32599690 PMCID: PMC7352760 DOI: 10.3390/ijms21124476
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Anthropometric data and biochemical profile of obese patients in preoperative and postoperative (six months after Roux-en-Y gastric bypass (RYGB)).
| Variables | Preoperative | Postoperative |
|---|---|---|
| N | 13 | 13 |
| Age (years) | 35.9 ± 9.2 | 36.2 ± 9.3 |
| Weight (kg) | 115.3 ± 19.4 | 85.3 ± 13.8 a |
| BMI (kg/m²) | 42.5 ± 7.0 | 31.8 ± 5.4 a |
| TC (mg/dL) | 177.4 ± 32.7 | 152.5 ± 28.4 a |
| HDL-C (mg/dL) | 41.3 ± 6.0 | 44.3 ± 8.1 |
| LDL-C (mg/dL) | 112.4 ± 27.6 | 88.6 ± 23.0 a |
| TG (mg/dL) | 129.7 ± 42.7 | 75.0 ± 27.0 a |
| Glucose (mg/dL) | 93.3 ± 13.5 | 83.6 ± 28.4 a |
Mean ± standard deviation; BMI: body mass index; %EWL: excess weight loss; TC: total cholesterol; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; TG: triglycerides; a: p-value < 0.05 compared to preoperative.
Upregulated genes after six months of RYGB that are involved in the onset of obesity and insulin pathway (p-value < 0.05). The fold change results were derived from the microarray assay.
| Symbol | Gene Name | Fold Change * |
|---|---|---|
| Obesity | ||
|
| Epidermal growth factor receptor pathway substrate 8 | 5.57 × 106 |
|
| Protein tyrosine phosphatase, non-receptor type 2 | 2.79 × 106 |
|
| ARP3 actin-related protein 3 homolog | 2.32 × 106 |
|
| Ribosomal protein S6 kinase | 2.45 × 106 |
|
| Mitogen-activated protein kinase 9 | 2.26 × 106 |
|
| RAP1B member of RAS oncogene family | 5.51 × 106 |
|
| Phospholipase A2 | 9.65 × 106 |
|
| Phosphoinositide-3-kinase, regulatory subunit 1 | 6.55 × 106 |
|
| ||
|
| Eukaryotic translation initiation factor 4E | 3.76 × 106 |
|
| Inhibitor of kappa light polypeptide gene enhancer in B-cells kinase beta | 3.90 × 106 |
|
| Phosphorylase kinase beta | 4.13 × 106 |
|
| Mitogen-activated protein kinase 9 | 2.26 × 106 |
|
| Protein phosphatase 1, catalytic subunit, beta isozyme | 2.19 × 106 |
|
| Suppressor of cytokine signaling 4 | 4.13 × 106 |
|
| Phosphoinositide-3-kinase, regulatory subunit 1 alpha | 6.55 × 106 |
* p-value < 0.05.
Figure 1Relative gene expression of phosphoinositide-3-kinase regulatory subunit 1 (PIK3R1) in pre- and postoperative periods. Both periods were composed of 13 patients. The fold change was calculated with the equation 2−∆∆. * p < 0.05.
Figure 2M values of evaluated CpG sites in promoter and body regions of PI3KR1 gene in pre- and postoperative periods of RYGB. * p < 0.05 shows CGs statistically significant in patients.
Figure 3Correlation between gene expression data (RT-qPCR) and the M value in the site cg20474370 of PI3KR1 in before RYGB (r = −0.709, p < 0.01). CT: cycle threshold.
Multiple linear regression showing the contribution of cg20474370 in gene expression.
| Gene Symbol (Gene ID) | Site | Gene Region | β | Adjusted Multiple | |
|---|---|---|---|---|---|
| cg20474370 | Body | −0.59 | 0.70 | 0.003 |
β: regression coefficient, r²: coefficient of determination. Regression was adjusted by endogenous control (RT-qPCR data).
Figure 4RYGB improves insulin and leptin resistance with consequent IRS-1 phosphorylation to initiate a signaling cascade that involves PIK3. PIK3 activation leads to Akt downstream signaling. The phosphorylation of IRS-1 triggered by PIK3 allows glucose to enter the cell improving blood glucose levels.
RT-qPCR TaqMan®Gene Expression Assays.
| Gene | ID (Gene Expression Assay) | Fragment (pb) |
|---|---|---|
|
| Hs00933163 | 82 |
|
| Hs99999905 | 122 |
|
| Hs99999903 | 171 |